Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
Lenvatinib (LENV) and atezolizumab/bevacizumab (ATE/BEV) have been approved as first-line regimens for the treatment of unresectable hepatocellular carcinoma (HCC). We aimed to compare their clinical efficacy and safety. Patients receiving ATE/BEV (<i>n</i> = 86) or LENV (<i>n</...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/7/1747 |
| _version_ | 1797440136528527360 |
|---|---|
| author | Beom Kyung Kim Jaekyung Cheon Hyeyeong Kim Beodeul Kang Yeonjung Ha Do Young Kim Seong Gyu Hwang Young Eun Chon Hong Jae Chon |
| author_facet | Beom Kyung Kim Jaekyung Cheon Hyeyeong Kim Beodeul Kang Yeonjung Ha Do Young Kim Seong Gyu Hwang Young Eun Chon Hong Jae Chon |
| author_sort | Beom Kyung Kim |
| collection | DOAJ |
| description | Lenvatinib (LENV) and atezolizumab/bevacizumab (ATE/BEV) have been approved as first-line regimens for the treatment of unresectable hepatocellular carcinoma (HCC). We aimed to compare their clinical efficacy and safety. Patients receiving ATE/BEV (<i>n</i> = 86) or LENV (<i>n</i> = 146) as first-line treatment were recruited from three academic hospitals in Korea. Overall survival (OS), progression-free survival (PFS), and radiological response were assessed according to the Response Evaluation Criteria in Solid Tumors. Clinical features of the two groups were balanced through propensity score (PS) matching with a 1:1 ratio and inverse probability of treatment weighting (IPTW) analyses. The median age was 62 years, with male predominance (83.6%). There was no significant difference in the objective response rate between the ATE/BEV and LENV groups (32.6% vs. 31.5%; <i>p</i> = 0.868). Neither median OS (not reached vs. 12.8 months; <i>p</i> = 0.357) nor PFS (5.7 vs. 6.0 months; <i>p</i> = 0.738) was different between ATE/BEV and LENV groups. PS-matched and IPTW analyses yielded comparable results in terms of OS and PFS (all <i>p</i> > 0.05). Grade ≥ 3 adverse events occurred in 42.8% and 21.9% of patients in the ATE/BEV and LENV groups, respectively (<i>p</i> = 0.141). The two first-line therapy regimens for unresectable HCC had comparable clinical efficacy and safety in real-world practice settings. Further studies with a larger sample size and longer follow-up are needed to validate these results. |
| first_indexed | 2024-03-09T12:02:48Z |
| format | Article |
| id | doaj.art-7f5637171ccf4b38b112b443effa4c29 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T12:02:48Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7f5637171ccf4b38b112b443effa4c292023-11-30T23:01:29ZengMDPI AGCancers2072-66942022-03-01147174710.3390/cancers14071747Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center StudyBeom Kyung Kim0Jaekyung Cheon1Hyeyeong Kim2Beodeul Kang3Yeonjung Ha4Do Young Kim5Seong Gyu Hwang6Young Eun Chon7Hong Jae Chon8Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, KoreaDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam 13496, KoreaDepartment of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, KoreaDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam 13496, KoreaDepartment of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam 13496, KoreaDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, KoreaDepartment of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam 13496, KoreaDepartment of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam 13496, KoreaDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam 13496, KoreaLenvatinib (LENV) and atezolizumab/bevacizumab (ATE/BEV) have been approved as first-line regimens for the treatment of unresectable hepatocellular carcinoma (HCC). We aimed to compare their clinical efficacy and safety. Patients receiving ATE/BEV (<i>n</i> = 86) or LENV (<i>n</i> = 146) as first-line treatment were recruited from three academic hospitals in Korea. Overall survival (OS), progression-free survival (PFS), and radiological response were assessed according to the Response Evaluation Criteria in Solid Tumors. Clinical features of the two groups were balanced through propensity score (PS) matching with a 1:1 ratio and inverse probability of treatment weighting (IPTW) analyses. The median age was 62 years, with male predominance (83.6%). There was no significant difference in the objective response rate between the ATE/BEV and LENV groups (32.6% vs. 31.5%; <i>p</i> = 0.868). Neither median OS (not reached vs. 12.8 months; <i>p</i> = 0.357) nor PFS (5.7 vs. 6.0 months; <i>p</i> = 0.738) was different between ATE/BEV and LENV groups. PS-matched and IPTW analyses yielded comparable results in terms of OS and PFS (all <i>p</i> > 0.05). Grade ≥ 3 adverse events occurred in 42.8% and 21.9% of patients in the ATE/BEV and LENV groups, respectively (<i>p</i> = 0.141). The two first-line therapy regimens for unresectable HCC had comparable clinical efficacy and safety in real-world practice settings. Further studies with a larger sample size and longer follow-up are needed to validate these results.https://www.mdpi.com/2072-6694/14/7/1747atezolizumabbevacizumabcomparisonhepatocellular carcinomalenvatinib |
| spellingShingle | Beom Kyung Kim Jaekyung Cheon Hyeyeong Kim Beodeul Kang Yeonjung Ha Do Young Kim Seong Gyu Hwang Young Eun Chon Hong Jae Chon Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study Cancers atezolizumab bevacizumab comparison hepatocellular carcinoma lenvatinib |
| title | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study |
| title_full | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study |
| title_fullStr | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study |
| title_full_unstemmed | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study |
| title_short | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study |
| title_sort | atezolizumab bevacizumab vs lenvatinib as first line therapy for unresectable hepatocellular carcinoma a real world multi center study |
| topic | atezolizumab bevacizumab comparison hepatocellular carcinoma lenvatinib |
| url | https://www.mdpi.com/2072-6694/14/7/1747 |
| work_keys_str_mv | AT beomkyungkim atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy AT jaekyungcheon atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy AT hyeyeongkim atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy AT beodeulkang atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy AT yeonjungha atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy AT doyoungkim atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy AT seonggyuhwang atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy AT youngeunchon atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy AT hongjaechon atezolizumabbevacizumabvslenvatinibasfirstlinetherapyforunresectablehepatocellularcarcinomaarealworldmulticenterstudy |